Molecular Form of Dietary DHA and its Bioavailability for the Brain

膳食 DHA 的分子形式及其对大脑的生物利用度

• 批准号: 8755224
• 负责人: PAPASANI V SUBBAIAH
• 金额: $ 19.94万
• 依托单位: UNIVERSITY OF ILLINOIS AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-01 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8755224
• 关键词: Abbreviations; Acids; Adipose tissue; Adult; Age; Alzheimer' s Disease; Appearance; Attenuated; Biological Availability; Blood - brain barrier anatomy; Blood Circulation; Brain; Caco-2 Cells; Cholesterol Esters; Chylomicrons; Cleaved cell; Cognitive; Defect; Diet; Dietary Phospholipid; Diffusion; Docosahexaenoic Acids; Eagles; Esters; Euphausiacea; Fatty Acids; Fish Oils; Fistula; Gas Chromatography; Gas-Liquid Chromatography; Goals; High Density Lipoproteins; Human; Hydrolysis; Intestinal Absorption; Intestines; Lead; Lecithin; Linolenic Acids; Lipase; Lipids; Lipoproteins; Liver; Lymph; Lysophosphatidylcholines; Mass Spectrum Analysis; Mental Retardation; Molecular; Monoglycerides; Neurons; Nonesterified Fatty Acids; Nutraceutical; Oils; Omega-3 Fatty Acids; Organ; Pancreas; Pancreatic enzyme; Phosphatidylethanolamine; Phospholipase A2; Phospholipids; Plasma; Positioning Attribute; Preparation; Prevention; Rattus; Relative (related person); Schizophrenia; Source; Testing; Tissues; Triglycerides; absorption; dietary supplements; feeding; healthy aging; high density lipoprotein phosphatidylcholine; improved; in vitro Model; in vivo Model; mouse model; nervous system disorder; novel; particle; prevent; public health relevance; uptake

DESCRIPTION (provided by applicant): DHA (docosahexaenoic acid) is an omega-3 fatty acid that is absolutely essential for the normal function of the brain, and its deficiency is known to be associated with several neurological disorders including Alzheimer's disease (AD), mental retardation, and schizophrenia. Although the brain contains the highest concentration of DHA among the organs, it is unable to synthesize DHA from the precursors, and needs to obtain it mostly from the diet. However, the presently available dietary supplements (fish oil, ethyl esters, krill oil, etc.) are inefficient in increasing the brain DHA levels, although they all easily enric the other organs with DHA. One possible reason for this is that while all other organs take up DHA in the form of whole lipoprotein particles, the brain takes it up through molecular diffusion of th DHA-containing lipids through the blood brain barrier, the most efficient carrier of DHA being lysophosphatidylcholine (LPC). Thus, the presence of DHA in plasma phospholipids is crucial for its brain uptake, and consequently, the absorption of dietary DHA in the form of phospholipids, rather than as triacylglycerol (TG), is highly advantageous. However, the presently available supplements of DHA are all absorbed as TG, because DHA in them is released as free fatty acid in the intestinal lumen by the pancreatic lipase and phospholipase A2, and incorporated into chylomicron TG. In this exploratory project, we will test the hypothesis that supplying the DHA as the sn-1 ester of phosphatidylcholine (PC) would result in its absorption as phospholipid because it escapes hydrolysis by the pancreatic enzymes, and thus will be more available for the eventual uptake by the brain. In Aim 1, we will study the absorption of different molecular forms of DHA (free acid, TG, sn-1 ester of PC, sn-2 ester of PC, and as LPC) employing an in vitro model (Caco-2 cells) as well as an in vivo model (lymph fistula rat). The relative amounts of DHA found in TG and PC of the absorbed lipids will be determined by tandem mass spectroscopy and gas chromatography. In Aim 2, we will feed the various molecular forms of DHA as supplements to the normal diets of adult rats for 4 weeks, and determine its appearance in plasma phospholipids, as well as its accumulation in the liver, adipose tissue and brain. If the proposed hypothesis is correct, the accumulation of DHA in the brain should be highest when it is present in the diet as sn-1 ester of PC or LPC. The results from these studies could lead to novel nutraceutical approaches to achieve adequate brain DHA levels for healthy aging and for prevention of neurological diseases such as AD, mental retardation, and schizophrenia.

产品描述（申请人提供）：DHA（二十二碳六烯酸）是一种ω-3脂肪酸，对大脑的正常功能至关重要，已知其缺乏 与包括阿尔茨海默病（AD）、精神发育迟滞和精神分裂症在内的几种神经系统疾病有关。虽然大脑中含有最高浓度的DHA，但它无法从前体合成DHA，并且需要主要从饮食中获得。然而，目前可用的膳食补充剂（鱼油，乙酯， 磷虾油等）在增加大脑DHA水平方面是无效的，尽管它们都很容易使其他器官获得DHA。一个可能的原因是，虽然所有其他器官都以整个脂蛋白颗粒的形式吸收DHA，但大脑通过含DHA的脂质的分子扩散穿过血脑屏障吸收DHA，DHA最有效的载体是溶血磷脂酰胆碱（LPC）。因此，血浆磷脂中DHA的存在对其脑摄取至关重要，因此，以磷脂形式而不是三酰甘油（TG）形式吸收膳食DHA是非常有利的。然而，目前可用的DHA补充剂都以TG形式吸收，因为其中的DHA在肠腔中通过胰脂肪酶和磷脂酶A2以游离脂肪酸形式释放，并掺入乳糜微粒TG中。在这个探索性的项目中，我们将测试这样一个假设，即以磷脂酰胆碱（PC）的sn-1酯的形式提供DHA将导致其作为磷脂被吸收，因为它逃避了胰腺酶的水解，因此将更容易被大脑最终吸收。 在目标1中，我们将采用体外模型（Caco-2细胞）和体内模型（淋巴瘘大鼠）研究不同分子形式的DHA（游离酸、TG、PC的sn-1酯、PC的sn-2酯和LPC）的吸收。将通过串联质谱和气相色谱法测定吸收脂质的TG和PC中发现的DHA的相对量。在目标2中，我们将喂养各种分子形式的DHA作为成年大鼠正常饮食的补充剂，持续4周，并确定其在血浆磷脂中的外观，以及其在肝脏，脂肪组织和大脑中的积累。如果提出的假设是正确的，那么当DHA作为PC或LPC的sn-1酯存在于饮食中时，DHA在大脑中的积累应该最高。这些研究的结果可能会导致新的营养方法，以达到足够的大脑DHA水平，以健康老龄化和预防神经系统疾病，如AD，精神发育迟滞和精神分裂症。